These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22868390)

  • 1. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine.
    Rombach SM; van den Bogaard B; de Groot E; Groener JE; Poorthuis BJ; Linthorst GE; van den Born BJ; Hollak CE; Aerts JM
    Hypertension; 2012 Oct; 60(4):998-1005. PubMed ID: 22868390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
    Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
    Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
    Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
    J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
    Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
    Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic progression to clinical phenotype in classic Fabry disease.
    Spada M; Kasper D; Pagliardini V; Biamino E; Giachero S; Porta F
    Ital J Pediatr; 2017 Jan; 43(1):1. PubMed ID: 28049500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combined use of three non-invasive atherosclerosis tests to predict vascular events in the elderly; carotid intima-media thickness, flow-mediated dilation of brachial artery and pulse wave velocity.
    Nagai K; Shibata S; Akishita M; Sudoh N; Obara T; Toba K; Kozaki K
    Atherosclerosis; 2013 Dec; 231(2):365-70. PubMed ID: 24267253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men.
    Yan RT; Anderson TJ; Charbonneau F; Title L; Verma S; Lonn E
    J Am Coll Cardiol; 2005 Jun; 45(12):1980-6. PubMed ID: 15963396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
    Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
    Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity.
    Kobayashi K; Akishita M; Yu W; Hashimoto M; Ohni M; Toba K
    Atherosclerosis; 2004 Mar; 173(1):13-8. PubMed ID: 15177119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the Cardiovascular Risk in Young Finns Study and the Health 2000 Survey.
    Koivistoinen T; Virtanen M; Hutri-Kähönen N; Lehtimäki T; Jula A; Juonala M; Moilanen L; Aatola H; Hyttinen J; Viikari JS; Raitakari OT; Kähönen M
    Atherosclerosis; 2012 Feb; 220(2):387-93. PubMed ID: 21871623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
    Politei J; Alberton V; Amoreo O; Antongiovanni N; Arán MN; Barán M; Cabrera G; Di Pietrantonio S; Durand C; Fainboim A; Frabasil J; Pizarro FG; Iotti R; Liern M; Perretta F; Ripeau D; Toniolo F; Trimarchi H; Rivas DV; Wallace E; Schenone AB
    Pediatr Nephrol; 2018 Nov; 33(11):2095-2101. PubMed ID: 29987457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.
    Krüger R; Tholey A; Jakoby T; Vogelsberger R; Mönnikes R; Rossmann H; Beck M; Lackner KJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():128-35. PubMed ID: 22138589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
    Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
    Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LysoGb3 quantification facilitates phenotypic categorization of Fabry disease patients: Insights gained by a novel MS/MS method.
    Kuchar L; Berna L; Poupetova H; Ledvinova J; Ruzicka P; Dostalova G; Reichmannova S; Asfaw B; Linhart A; Sikora J
    Clin Chim Acta; 2024 Jul; 561():119824. PubMed ID: 38906396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients.
    Duro G; Anania M; Zizzo C; Francofonte D; Giacalone I; D'Errico A; Marsana EM; Colomba P
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated globotriaosylsphingosine is a hallmark of Fabry disease.
    Aerts JM; Groener JE; Kuiper S; Donker-Koopman WE; Strijland A; Ottenhoff R; van Roomen C; Mirzaian M; Wijburg FA; Linthorst GE; Vedder AC; Rombach SM; Cox-Brinkman J; Somerharju P; Boot RG; Hollak CE; Brady RO; Poorthuis BJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):2812-7. PubMed ID: 18287059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary Microvascular function, Peripheral Endothelial Function and Carotid IMT in beta-thalassemia minor.
    Gullu H; Caliskan M; Caliskan Z; Unler GK; Ermisler E; Ciftci O; Guven A; Muderrisoglu H
    Thromb Res; 2013 Jun; 131(6):e247-52. PubMed ID: 23683324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry.
    Gold H; Mirzaian M; Dekker N; Joao Ferraz M; Lugtenburg J; Codée JD; van der Marel GA; Overkleeft HS; Linthorst GE; Groener JE; Aerts JM; Poorthuis BJ
    Clin Chem; 2013 Mar; 59(3):547-56. PubMed ID: 23237761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.